scispace - formally typeset
Search or ask a question
Institution

Université de Montréal

EducationMontreal, Quebec, Canada
About: Université de Montréal is a education organization based out in Montreal, Quebec, Canada. It is known for research contribution in the topics: Population & Poison control. The organization has 45641 authors who have published 100476 publications receiving 4004007 citations. The organization is also known as: University of Montreal & UdeM.


Papers
More filters
Journal ArticleDOI
Gary A. Churchill, David C. Airey1, Hooman Allayee2, Joe M. Angel3, Alan D. Attie4, Jackson Beatty5, Willam D. Beavis6, John K. Belknap7, Beth Bennett8, Wade H. Berrettini9, André Bleich10, Molly A. Bogue, Karl W. Broman11, Kari J. Buck12, Edward S. Buckler13, Margit Burmeister14, Elissa J. Chesler15, James M. Cheverud16, Steven J. Clapcote17, Melloni N. Cook18, Roger D. Cox19, John C. Crabbe12, Wim E. Crusio20, Ariel Darvasi21, Christian F. Deschepper22, Rebecca W. Doerge23, Charles R. Farber24, Jiri Forejt25, Daniel Gaile26, Steven J. Garlow27, Hartmut Geiger28, Howard K. Gershenfeld29, Terry Gordon30, Jing Gu15, Weikuan Gu15, Gerald de Haan31, Nancy L. Hayes32, Craig Heller33, Heinz Himmelbauer34, Robert Hitzemann12, Kent W. Hunter35, Hui-Chen Hsu36, Fuad A. Iraqi37, Boris Ivandic38, Howard J. Jacob39, Ritsert C. Jansen31, Karl J. Jepsen40, Dabney K. Johnson41, Thomas E. Johnson8, Gerd Kempermann42, Christina Kendziorski4, Malak Kotb15, R. Frank Kooy43, Bastien Llamas22, Frank Lammert44, J. M. Lassalle45, Pedro R. Lowenstein5, Lu Lu15, Aldons J. Lusis5, Kenneth F. Manly15, Ralph S. Marcucio46, Doug Matthews18, Juan F. Medrano24, Darla R. Miller41, Guy Mittleman18, Beverly A. Mock35, Jeffrey S. Mogil47, Xavier Montagutelli48, Grant Morahan49, David G. Morris50, Richard Mott51, Joseph H. Nadeau52, Hiroki Nagase53, Richard S. Nowakowski32, Bruce F. O'Hara54, Alexander V. Osadchuk, Grier P. Page36, Beverly Paigen, Kenneth Paigen, Abraham A. Palmer, Huei Ju Pan, Leena Peltonen-Palotie55, Leena Peltonen-Palotie5, Jeremy L. Peirce15, Daniel Pomp56, Michal Pravenec25, Daniel R. Prows28, Zonghua Qi1, Roger H. Reeves11, John C. Roder17, Glenn D. Rosen57, Eric E. Schadt58, Leonard C. Schalkwyk59, Ze'ev Seltzer17, Kazuhiro Shimomura60, Siming Shou61, Mikko J. Sillanpää55, Linda D. Siracusa62, Hans-Willem Snoeck40, Jimmy L. Spearow24, Karen L. Svenson, Lisa M. Tarantino63, David W. Threadgill64, Linda A. Toth65, William Valdar51, Fernando Pardo-Manuel de Villena64, Craig H Warden24, Steve Whatley59, Robert W. Williams15, Tom Wiltshire63, Nengjun Yi36, Dabao Zhang66, Min Zhang13, Fei Zou64 
Vanderbilt University1, University of Southern California2, University of Texas MD Anderson Cancer Center3, University of Wisconsin-Madison4, University of California, Los Angeles5, National Center for Genome Resources6, Portland VA Medical Center7, University of Colorado Boulder8, University of Pennsylvania9, Hannover Medical School10, Johns Hopkins University11, Oregon Health & Science University12, Cornell University13, University of Michigan14, University of Tennessee Health Science Center15, Washington University in St. Louis16, University of Toronto17, University of Memphis18, Medical Research Council19, University of Massachusetts Medical School20, Hebrew University of Jerusalem21, Université de Montréal22, Purdue University23, University of California, Davis24, Academy of Sciences of the Czech Republic25, University at Buffalo26, Emory University27, University of Cincinnati28, University of Texas Southwestern Medical Center29, New York University30, University of Groningen31, Rutgers University32, Stanford University33, Max Planck Society34, National Institutes of Health35, University of Alabama at Birmingham36, International Livestock Research Institute37, Heidelberg University38, Medical College of Wisconsin39, Icahn School of Medicine at Mount Sinai40, Oak Ridge National Laboratory41, Charité42, University of Antwerp43, RWTH Aachen University44, Paul Sabatier University45, University of California, San Francisco46, McGill University47, Pasteur Institute48, University of Western Australia49, Yale University50, University of Oxford51, Case Western Reserve University52, Roswell Park Cancer Institute53, University of Kentucky54, University of Helsinki55, University of Nebraska–Lincoln56, Harvard University57, Merck & Co.58, King's College London59, Northwestern University60, Shriners Hospitals for Children61, Thomas Jefferson University62, Novartis63, University of North Carolina at Chapel Hill64, Southern Illinois University Carbondale65, University of Rochester66
TL;DR: The Collaborative Cross will provide a common reference panel specifically designed for the integrative analysis of complex systems and will change the way the authors approach human health and disease.
Abstract: The goal of the Complex Trait Consortium is to promote the development of resources that can be used to understand, treat and ultimately prevent pervasive human diseases. Existing and proposed mouse resources that are optimized to study the actions of isolated genetic loci on a fixed background are less effective for studying intact polygenic networks and interactions among genes, environments, pathogens and other factors. The Collaborative Cross will provide a common reference panel specifically designed for the integrative analysis of complex systems and will change the way we approach human health and disease.

1,040 citations

Journal ArticleDOI
TL;DR: Findings reinforce the view that emotional self-regulation is normally implemented by a neural circuit comprising various prefrontal regions and subcortical limbic structures and suggest that humans have the capacity to influence the electrochemical dynamics of their brains, by voluntarily changing the nature of the mind processes unfolding in the psychological space.
Abstract: A fundamental question about the relationship between cognition and emotion concerns the neural substrate underlying emotional self-regulation. To address this issue, brain activation was measured in normal male subjects while they either responded in a normal manner to erotic film excerpts or voluntarily attempted to inhibit the sexual arousal induced by viewing erotic stimuli. Results demonstrated that the sexual arousal experienced, in response to the erotic film excerpts, was associated with activation in "limbic" and paralimbic structures, such as the right amygdala, right anterior temporal pole, and hypothalamus. In addition, the attempted inhibition of the sexual arousal generated by viewing the erotic stimuli was associated with activation of the right superior frontal gyrus and right anterior cingulate gyrus. No activation was found in limbic areas. These findings reinforce the view that emotional self-regulation is normally implemented by a neural circuit comprising various prefrontal regions and subcortical limbic structures. They also suggest that humans have the capacity to influence the electrochemical dynamics of their brains, by voluntarily changing the nature of the mind processes unfolding in the psychological space.

1,037 citations

Journal ArticleDOI
TL;DR: The 2006 Second International Working Meeting on Frailty and Aging as mentioned in this paper discussed the distinction between frailty and aging, its relationship with chronic disease, and the critical domains in its operational definition.
Abstract: Clinicians and researchers have shown increasing interest in frailty. Yet, there is still considerable uncertainty regarding the concept and its definition. In this article, we present perspectives on key issues and controversies discussed by scientists from 13 different countries, representing a diverse range of disciplines, at the 2006 Second International Working Meeting on Frailty and Aging. The following fundamental questions are discussed: What is the distinction, if any, between frailty and aging? What is its relationship with chronic disease? Is frailty a syndrome or a series of age-related impairments that predict adverse outcomes? What are the critical domains in its operational definition? Is frailty a useful concept? The implications of different models and approaches are examined. Although consensus has yet to be attained, work accomplished to date has opened exciting new horizons. The article concludes with suggested directions for future research.

1,030 citations

Journal ArticleDOI
TL;DR: The study suggests that olaparib is a promising treatment for women with ovarian cancer and further assessment of the drug in clinical trials is needed.
Abstract: Summary Background Olaparib (AZD2281) is a small-molecule, potent oral poly(ADP-ribose) polymerase (PARP) inhibitor. We aimed to assess the safety and tolerability of this drug in patients without BRCA1 or BRCA2 mutations with advanced triple-negative breast cancer or high-grade serous and/or undifferentiated ovarian cancer. Methods In this phase 2, multicentre, open-label, non-randomised study, women with advanced high-grade serous and/or undifferentiated ovarian carcinoma or triple-negative breast cancer were enrolled and received olaparib 400 mg twice a day. Patients were stratified according to whether they had a BRCA1 or BRCA2 mutation or not. The primary endpoint was objective response rate by Response Evaluation Criteria In Solid Tumors (RECIST). All patients who received treatment were included in the analysis of toxic effects, and patients who had measurable lesions at baseline were included in the primary efficacy analysis. This trial is registered at ClinicalTrials.gov, number NCT00679783. Findings 91 patients were enrolled (65 with ovarian cancer and 26 breast cancer) and 90 were treated between July 8, 2008, and Sept 24, 2009. In the ovarian cancer cohorts, 64 patients received treatment. 63 patients had target lesions and therefore were evaluable for objective response as per RECIST. In these patients, confirmed objective responses were seen in seven (41%; 95% CI 22–64) of 17 patients with BRCA1 or BRCA2 mutations and 11 (24%; 14–38) of 46 without mutations. No confirmed objective responses were reported in patients with breast cancer. The most common adverse events were fatigue (45 [70%] of patients with ovarian cancer, 13 [50%] of patients with breast cancer), nausea (42 [66%] and 16 [62%]), vomiting (25 [39%] and nine [35%]), and decreased appetite (23 [36%] and seven [27%]). Interpretation Our study suggests that olaparib is a promising treatment for women with ovarian cancer and further assessment of the drug in clinical trials is needed. Funding AstraZeneca.

1,030 citations

Journal ArticleDOI
TL;DR: In this paper, a maximal multistage 20-m shuttle run test for the prediction of O2 max was proposed and validated using the retroextrapolation method, and the results showed that it is a valid and reliable test for predicting the O2max of male and female adults.
Abstract: In order to validate a maximal multistage 20-m shuttle run test for the prediction of $$\dot V$$ O2 max, 91 adults (32 females and 59 males, aged 27.3±9.2 and 24.8±5.5 year respectively and with mean $$\dot V$$ O2 max (± SD) of 39.3±8.3 and 51.6±7.8 ml·kg−1·min−1 respectively) performed the test and had $$\dot V$$ O2 max estimated by the retroextrapolation method (extrapolation to time zero of recovery of the exponential least squares regression of the first four 20-s recovery $$\dot V$$ O2 values). Starting at 8 km·h−1 and increasing by 0.5 km·h−1 every 2 min, the 20-m shuttle run test enabled prediction of the $$\dot V$$ O2 max (y, ml·kg−1·min−1) from the maximal speed (x, km·h−1) by means of the following regression equation: y=5.857x — 19.458; r=0.84 and SEE=5.4. Later, the multistage protocol was slightly modified to its final version, in which the test started at stage 7 Met and continued with a 1 Met (3.5 ml O2·kg−1·min−1) increment every 2 min. Twenty-five of the 91 subjects performed the 20-m shuttle test twice, once on a hard, low-friction surface (vinyl-asbestos tiles) and another time on a rubber floor, as well as a walking maximal multistage test on an inclined treadmill. There was no difference between the means of these tests or between the slopes of the $$\dot V$$ O2max — maximal speed regressions for the two types of surfaces. The 20-m shuttle run test and another maximal multistage field test involving continuous track running gave comparable results (r=0.92, SEE=2.6 ml O2·kg−1·min−1, n=70). Finally, test and retest of the 20-m shuttle run test also yielded comparable results (r=0.975, SEE=2.0 ml O2·kg−1·min−1, n=50). It is concluded that the 20-m shuttle run test is a valid and reliable test for the prediction of the $$\dot V$$ O2 max of male and female adults, individually or in groups, on most gymnasium surfaces.

1,030 citations


Authors

Showing all 45957 results

NameH-indexPapersCitations
Yoshua Bengio2021033420313
Alan C. Evans183866134642
Richard H. Friend1691182140032
Anders Björklund16576984268
Charles N. Serhan15872884810
Fernando Rivadeneira14662886582
C. Dallapiccola1361717101947
Michael J. Meaney13660481128
Claude Leroy135117088604
Georges Azuelos134129490690
Phillip Gutierrez133139196205
Danny Miller13351271238
Henry T. Lynch13392586270
Stanley Nattel13277865700
Lucie Gauthier13267964794
Network Information
Related Institutions (5)
University of Toronto
294.9K papers, 13.5M citations

96% related

University of Pennsylvania
257.6K papers, 14.1M citations

93% related

University of Wisconsin-Madison
237.5K papers, 11.8M citations

92% related

University of Minnesota
257.9K papers, 11.9M citations

92% related

Harvard University
530.3K papers, 38.1M citations

92% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
2023118
2022485
20216,077
20205,753
20195,212
20184,696